for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Genprex Inc

GNPX.OQ

Latest Trade

0.39USD

Change

-0.04(-9.72%)

Volume

5,903

Today's Range

0.38

 - 

0.43

52 Week Range

0.38

 - 

2.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.43
Open
0.43
Volume
5,903
3M AVG Volume
1.79
Today's High
0.43
Today's Low
0.38
52 Week High
2.25
52 Week Low
0.38
Shares Out (MIL)
15.84
Market Cap (MIL)
6.86
Forward P/E
-0.72
Dividend (Yield %)
--

Latest Developments

More

Genprex Collaborators Report Positive Tusc2 And Checkpoint Blockade Preclinical Data

Genprex Inc Files For Offering Of Up To 4.6 Million Shares Of Co's Common Stock By The Selling Stockholders

Genprex Inc Files Prospectus Related To Offering Of Up To 4.6 Mln Shares Of Common Stock - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Genprex Inc

Genprex, Inc. is a clinical stage gene therapy company. The Company is focused on developing cancer-based upon its novel proprietary technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. The Company’s Oncoprex is lead product candidate, is the subject of an ongoing Phase I/II clinical trials at The University of Texas MD Anderson Cancer Center in patients with late stage non-small cell lung cancer, or NSCLC. Oncoprex gene therapy platform may also be effective with respect to other types of cancer, including breast, head and neck, renal cell (kidney), soft tissue cancer. The Company’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The Company’s Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis.

Industry

Biotechnology & Drugs

Contact Info

1601 Trinity St Bldg B

+1.512.5377997

https://www.genprex.com/

Executive Leadership

J. Rodney Varner

Chairman of the Board, Chief Executive Officer, Secretary

Julien L. Pham

President, Chief Operating Officer

Ryan M. Confer

Chief Financial Officer

David E. Friedman

Director

Robert W. Pearson

Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.900

2019(E)

-0.600
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.15
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-128.06
Return on Equity (TTM)
-119.77

Latest News

Latest News

BRIEF-Genprex Inc Files Prospectus Related To Offering Of Up To 4.6 Mln Shares Of Common Stock - SEC Filing

* GENPREX INC FILES PROSPECTUS RELATED TO OFFERING OF UP TO 4.6 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2LmssJd) Further company coverage:

BRIEF-Genprex Announces $10 Million Private Placement

* GENPREX INC - PER SHARE PURCHASE PRICE OF COMMON STOCK IS $12.07, INITIAL EXERCISE PRICE FOR WARRANTS IS $15.62 PER SHARE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Genprex Files For Non-Timely 10 K With U.S. SEC

* GENPREX INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC Source text for Eikon: [https://bit.ly/2q36an3] Further company coverage:

BRIEF-Genprex says IPO priced at $5.00 per share

* Genprex, Inc. commences initial public offering and sets price

BRIEF-Genprex Inc sees IPO of 5.6 mln shares of its common stock

* Genprex Inc sees IPO of 5.6 million shares of its common stock priced between $4.00 and $6.00 per share - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up